AbbVie (ABBV) Qulipta Achieves Clinical Win for Menstrual Migraine

AbbVie (NYSE: ABBV) recently announced positive Phase 3 trial results for Qulipta, a migraine treatment, showing significant reductions in migraine days during the perimenstrual period compared to a placebo. Qulipta also met all secondary endpoints without introducing new safety signals. This success may lead to a label expansion, with an estimated market opportunity of over nine million adult patients in the U.S. alone for menstrual migraines. The ability of Qulipta to penetrate this market will depend on health insurance coverage and patient's perceptions of their migraine severity.